11C-PBB3 PET in PD: does alpha-synuclein pathology start in axonal terminals?
Objective: To use 11C-PBB3 PET binding to monitor alpha-synuclein (a-syn) pathology in PD subjects in vivo. Background: In previous work we have shown binding of…The role of Synaptic vesicle protein 2A (SV2A) in patients with Parkinson’s disease dementia and Dementia with Lewy bodies: An in vivo [11C]UCB-J PET study
Objective: We aimed to investigate the role of synaptic vesicle glycoprotein 2A (SV2A) in Parkinson’s disease dementia (PDD) and Dementia with Lewy bodies (DLB) using…Multimodal PET and fcMRI reveals regional modulation by STN DBS correlating to motor outcomes
Objective: To define brain networks modulated by deep brain stimulation (DBS) of the subthalamic nucleus (STN) and correlate connectivity with motor outcomes. Background: STN DBS…Relationship between symptoms and regional density of metabotropic glutamate receptors subtype 1 measured with 11C-ITMM PET in de novo Parkinson’s disease
Objective: To investigate correlations of motor and non-motor symptoms with the brain densitiesof the metabotropic glutamate receptor subtype 1 (mGluR1) in de novo Parkinson’s disease…Comparison between [11C]PE2I PET and [123I]FP-CIT SPECT as markers of DAT expression in early Parkinson’s disease
Objective: To compare single-photon emission computed tomography (SPECT) with [123I]FP-CIT and positron emission tomography (PET) with [11C]PE2I as markers of dopamine transporter (DAT) loss in…FDG PET: a good predictive tool for CNS inflammation
Objective: 1)When to suspect an underlying autoimmune process in patients presenting with parkinsonism. 2)To highlight the importance of FDG PET as a complementary exam in…Imaging Parkinson’s disease pathology: A comparison between neuromelanin-sensitive MRI, susceptibility weighted imaging and [11C]PE2I DAT PET
Objective: We compared 2 novel MRI techniques: neuromelanin-sensitive MRI (NM-MRI) and susceptibility weighted imaging (SWI) with [11C]PE2I PET in order to establish their validity as biomarkers…Characteristics of the clinical and cerebral metabolism in Parkinson’s disease with atrophy in nucleus basalis of Meynert
Objective: We investigated characteristics of clinical and cerebral glucose metabolic abnormalities in Parkinson’s disease (PD) with atrophy in the nucleus basalis of Meynert (NBM). Background:…Mitochondrial Complex 1, Sigma 1 Receptor and Synaptic Vesicle protein 2A density in early de novo patients with Parkinson’s Disease: pilot PET data
Objective: In this study, we evaluated the density of Mitochondrial complex 1 (MC1), sigma 1 receptor (s1R) and Synaptic Vesicle protein 2A (SV2A) in early…Cerebrotendinous Xanthomatosis presenting Parkinsonism with bilateral iron accumulation in the basal ganglia
Objective: Cerebrontendinous xanthomatosis(CTX) is a treatable, autosomal recessive, lipid storage disorder disease. Herein, we present a case of CTX. It aims to refresh and improve…
- « Previous Page
- 1
- …
- 18
- 19
- 20
- 21
- 22
- …
- 33
- Next Page »